While Amazon is up 17%, the Nasdaq party is being spoiled by the 17% collapse in Biogen following its aggressive guidance cut. As we noted previously, Biogen is the 4th most profitable biotech company and this 'scare' is weighing heavy on Janet Yellen's favorite short industry as the entire Biotech index is sliding.
Amazon Up 17%
Biogen Down 17%...

2015 Financial Guidance
As previously announced, the Company plans to provide annual financial guidance and one update per year. Biogen’s mid-year update to its full year 2015 financial guidance consists of the following components:
- Revenue growth is expected to be approximately 6% to 8% compared to 2014, a decrease from prior guidance based largely on revised expectations for the growth of TECFIDERA.
- R&D expense is expected to be approximately 19% to 20% of total revenue, unchanged from prior guidance.
- SG&A expense is expected to be approximately 20% to 21% of total revenue, unchanged from prior guidance.
- GAAP diluted EPS is expected to be between $14.25 and $14.70, a decrease from prior guidance.
- Non-GAAP diluted EPS is expected to be between $15.50 and $15.95, a decrease from prior guidance.
- Biogen may incur charges, realize gains or experience other events in 2015 that could cause actual results to vary from this guidance.
Don't forget, Biogen is the 4th most profitable Biotech...
And Nasdaq is getting hammereed as the Biotech contagion spreads...
Charts: Bloomberg



